Last reviewed · How we verify
Colistimethate sodium for injection
Colistimethate sodium is a prodrug of colistin that disrupts bacterial cell membranes by binding to lipopolysaccharides and phospholipids, leading to cell lysis and death.
Colistimethate sodium is a prodrug of colistin that disrupts bacterial cell membranes by binding to lipopolysaccharides and phospholipids, leading to cell lysis and death. Used for Infections caused by multidrug-resistant gram-negative bacteria (e.g., Pseudomonas aeruginosa, Acinetobacter baumannii), Hospital-acquired pneumonia and other serious infections in patients with limited treatment options.
At a glance
| Generic name | Colistimethate sodium for injection |
|---|---|
| Sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Drug class | Polymyxin antibiotic |
| Target | Bacterial lipopolysaccharide and phospholipid membranes |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Colistimethate sodium (also known as colistin methanesulfonate) is converted in vivo to colistin, a polymyxin antibiotic. Colistin acts as a cationic detergent that interacts with the outer membrane of gram-negative bacteria, disrupting membrane integrity and causing leakage of cellular contents. It is primarily used against multidrug-resistant gram-negative pathogens, particularly Pseudomonas aeruginosa and Acinetobacter baumannii.
Approved indications
- Infections caused by multidrug-resistant gram-negative bacteria (e.g., Pseudomonas aeruginosa, Acinetobacter baumannii)
- Hospital-acquired pneumonia and other serious infections in patients with limited treatment options
Common side effects
- Nephrotoxicity (acute kidney injury)
- Neurotoxicity (paresthesia, dizziness)
- Injection site reactions
- Fever
Key clinical trials
- Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection (NA)
- Comparative Study of Clinical Outcomes and Safety Between Colistin and Tigecycline (PHASE4)
- A Clinical Trial for the Treatment of Carbapenem Resistant Gram-negative Bacterial Infection With Colistimethate Sodium for Injection (PHASE3)
- Effect of Different Colistin Doses on Clinical Outcome of Pediatric Cancer Patients With Gram Negative Infections (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: